Rebalance neurotransmitter precursors with supplement
- Trial ID
- NCT07115563
- Official Title
- Effects of Targeted Amino Acid Supplementation for People With Parkinson's Disease on Amino Acid Profiles and Health Related Markers
- Goal
- Rebalance neurotransmitter precursors with supplement
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Cristina Colon-Semenza
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease (PD)
- Interventions
- Targeted Amino Acid Supplement, Control (placebo)
Plain-Language Summary
The goal is to find out whether a targeted blend of amino acids can change blood amino acid profiles and related health markers in people with Parkinson's, which might influence neurotransmitter balance and overall metabolism. The approach gives a daily supplement of selected amino acids versus placebo, aiming to boost or rebalance precursors for neurotransmitters and protein synthesis, and the study will watch for interactions with levodopa because some amino acids can compete with it for transport into the brain. Participants should be age 60 to 80 with idiopathic Parkinson's, on dopamine replacement therapy like levodopa for at least two years and on a stable dose for three months, with exclusions for significant cognitive impairment, deep brain stimulation, bleeding disorders, or other unstable medical issues.
Locations
- University of Connecticut, Storrs, Connecticut, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Targeted Amino Acid Supplement. The goal is to find out whether a targeted blend of amino acids can change blood amino acid profiles and related health markers in people with Parkinson's, which might influence neurotransmitter balance and overall metabolism. The approach gives a daily supplement of selected amino acids versus placebo, aiming to boost or rebalance precursors for neurotransmitters and protein synthesis, and the study will watch for interactions with levodopa because some amino acids can compete with it for transport into the brain. Participants should be age 60 to 80 with idiopathic Parkinson's, on dopamine replacement therapy like levodopa for at least two years and on a stable dose for three months, with exclusions for significant cognitive impairment, deep brain stimulation, bleeding disorders, or other unstable medical issues.
- Who can participate?
- Participants must be between 60 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 10 months.